Polymorphism, Suicidal Behavior, Tryptophan Metabolism Alterations
Conditions
Keywords
sucidal behavior, Inflammation, Kynurenines
Brief summary
Current research has shown that an imbalance in the Kynurenine pathway plays a role in the physiopathology of neurogenerative and mental disorders (with a decrease in neuroprotective metabolites and an increase in neurotoxic products). So far the research has concentrated on the enzymes IDO 1/2, KAT (1-4), KMO and ACMSD which are the key players in this pathway. Several polymorphisms affecting these enzymes have been associated with certain disorders characterized by a deregulation of the inflammation and immune response (McCauley et al 2009,Tardito et al 2013, Lee et al 2014), but the link between these enzymes and suicidal behavior is not yet clear. The investigators hypothesize that people with history of suicide attempt would have a genetic alterations of the kynurenine pathway specific for suicidal behavior.
Interventions
GENETICSNP (single nucleotide polymorphism) genotyping
We use TaqMan technique to perform SNP genotyping. The PCR reactions are carried out using the Roche Light Cycler 480 thermal cycler following the protocol recommended by Thermo Fisher Scientific. Then, replication of 10% of the samples is carried out.
Sponsors
Universidad Autonoma de Madrid
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* For the Sucide attempters group: Any patient aged 18 or over who has made at least one suicide attempt. * For the two control groups: Any patient aged 18 or over, suffering from depression but has never attempted to commit suicide and any healthy subject who has never had any mental disorders.
Exclusion criteria
* Any patient who has expressed opposition to the use of his/her data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The genotypic and allelelic frequencies of IDO1 rs7820268 SNP in each studied group | 24 months | The frequencies of this SNP will be measured as a percentage |
| The genotypic and allelelic frequencies of IDO2 rs10109853 SNP in each studied group | 24 months | The frequencies of this SNP will be measured as a percentage |
| The genotypic and allelelic frequencies of KMO rs1053230 SNP in each studied group | 24 months | The frequencies of this SNP will be measured as a percentage |
| The genotypic and allelelic frequencies of KAT1 rs10988134 SNP in each studied group | 24 months | The frequencies of this SNP will be measured as a percentage |
| The genotypic and allelelic frequencies of ACMSD rs2121337 SNP in each studied group | 24 months | The frequencies of this SNP will be measured as a percentage |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of suicide attempts | 24 months | The number of suicide attempts will be recorded as a number |
| Age of subjects | 24 months | The age will be recorded for statistical purposes |
| Age of first suicide attempt | 24 months | Age of first suicide attempt will be recorded as a number |
| Gender of subjects | 24 months | The gender will be recorded for statistical purposes |
| Marital status of subjects | 24 months | The marital status will be recorded as a number and a percentage |
| Education level of subjects | 24 months | the education level will be recorded as a number and a percentage |
| Diagnosis | 24 months | The diagnosis will be recorded as a number and a percentage |
Countries
France, Spain
Outcome results
None listed